Reuters logo
BRIEF-Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program
November 24, 2017 / 11:22 AM / 19 days ago

BRIEF-Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program

Nov 24 (Reuters) - Nektar Therapeutics

* Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs

* Nektar Therapeutics - costs related to concluding co’s activities related to Bayer’s phase 3 Amikacin Inhale clinical program under 2007 agreement

* Nektar Therapeutics - based on discussion with Bayer, Nektar does not expect Bayer to move forward any further with the Amikacin Inhale program Source text: (bit.ly/2A32qHJ) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below